Medicare's $50 GLP-1 Program, an Altered Drug Trial & Cyclospora's 18-State Spread
7/10/202612 min
Friday, July 10, 2026
In today's episode, Dr. Will Flanary / Dr. Glaucomflecken (@drglaucomflecken) & Eva Johnson cover the retraction of the Advocate trial after FDA reviewers found the avacopan (Tavneos) dataset was unblinded, re-adjudicated, and altered before being relocked, throwing its approval for ANCA-associated vasculitis into doubt. They break down Medicare's new GLP-1 Bridge program, which offers eligible Part D beneficiaries drugs like Wegovy and Zepbound at $50 a month through the end of 2027, and why that copay sits outside normal Part D accounting. They also track a Cyclospora outbreak now reported across 18 states and why routine washing does not reliably kill it. Plus: they also discuss Alibaba's $600 million fentanyl-precursor settlement, the WHO's first emergency-use Ebola (Bundibugyo) diagnostic, France's deadly heat wave, and more.
Coverage Timeline:
(00:00) Intro
(01:04) Vasculitis Trial Retracted:
(03:44) Medicare’s GLP‑1 Bridge
(06:02) Parasite, Ebola, Heat Wave
Have a story, think we missed something, want to say hi, or curious to learn about the Medlines team? Visit www.medlinespod.com or email medlines@human-content.com.
Sources & Media Attributions for Today's Episode Available At:
Medlines is a Human Content Production
Clips
Transcript preview
First 90 secondsWill Flanary· Host0:07
Welcome to Medline, your weekly resource for quick, credible, on-the-go medical news for those of us too busy practicing to remember whether or not we reapplied sunscreen. Brought to you by the New England Journal of Medicine.
Eva Johnson· Host0:18
Today is July 10th, 2026. At the desk today, bringing you the latest headlines in healthcare, I'm Eva Johnson.
Will Flanary· Host0:25
And I'm Dr. Will Flannery. Over the last week, the New England Journal of Medicine retracted a major vasculitis trial after FDA findings raised serious questions about the data behind Avacopan. Medicare launched a new GLP-1 bridge program, offering some weight loss drugs to eligible beneficiaries. And keep washing your produce. A diarrhea-causing parasite is spreading across 18 states.
Eva Johnson· Host0:48
But before we begin, today's trivia question. What class of drugs was first developed from the venom of the Gila monster?
Will Flanary· Host0:58
Oh, that's a good one. All right. Stick around. We'll find out the answer at the end. And now, this week's Medlines. Our first story is about Avacopan, the Advocate trial, and a retraction with direct implications for current patient care. Avacopan, sold as Tavneos, was approved for ANCA-associated vasculitis, a rare autoimmune disease that inflames small and medium blood vessels. The drug was meant to control the disease while reducing exposure to high-dose glucocorticoids